Acute Lymphoblastic Leukemia (ALL) Clinical Trial Monitor

Active Phase 3 ALL Programs (2026)

Active Phase 2 Programs — CAR-T and Immunotherapy

Ph+ ALL and TKI Combinations

What Is Acute Lymphoblastic Leukemia?

Acute lymphoblastic leukemia (ALL) is a malignancy of immature B or T lymphocyte precursors (lymphoblasts). ALL is the most common childhood cancer — representing ~25% of pediatric cancers — and is curable in approximately 90% of children with modern chemotherapy. In adults, however, ALL remains challenging: complete remission rates are high (85-90%) but relapse-free survival drops to 40-50% at 5 years for standard-risk adult disease, and worse for high-risk subgroups.

ALL is broadly classified by lineage (B-cell ALL [B-ALL], ~85%; T-cell ALL [T-ALL], ~15%) and by key cytogenetic/molecular features. The major subtypes include: (1) Philadelphia chromosome-positive ALL (Ph+ ALL, BCR-ABL1) — occurs in ~25% of adult ALL, requires TKI + chemotherapy or immunotherapy; (2) Ph-like ALL — a genomic subtype with similar gene expression to Ph+ ALL but lacking BCR-ABL1, carrying similarly poor prognosis; (3) KMT2A-rearranged ALL — present in ~5-10% of adult ALL, sensitive to menin inhibitors; (4) T-ALL — distinct biology from B-ALL, with active trials exploring novel agents including venetoclax, nelarabine combinations, and CD7-directed therapies.

The Immunotherapy Revolution in B-ALL

Blinatumomab: From Salvage to Frontline

The trajectory of blinatumomab in ALL mirrors a now-familiar pattern in oncology: approval in relapsed/refractory disease → MRD+ consolidation → frontline combination. The pivotal E1910 trial demonstrated that adding blinatumomab to standard consolidation chemotherapy in adults with newly diagnosed Ph-negative B-ALL improved 3-year OS from 68% to 85%. This result was practice-changing and immediately incorporated into NCCN guidelines. Active trials are now testing whether blinatumomab can be moved even earlier — into induction — and whether it can replace or reduce chemotherapy intensity in subgroups. The key open question is whether blinatumomab's T-cell engagement mechanism can be fully exploited in the frontline setting, where T-cell health is better preserved than in heavily pretreated patients.

CD19 CAR-T in Adult ALL

Two CD19-directed CAR-T therapies are FDA-approved in ALL: tisagenlecleucel (Kymriah, Novartis) for pediatric and young adult (up to age 25) R/R B-ALL; brexucabtagene autoleucel (Tecartus, Kite/Gilead) for adult R/R B-ALL. Both achieve complete remission in approximately 70-80% of patients, with a subset achieving durable long-term remissions. The clinical challenges are cytokine release syndrome (CRS), neurotoxicity (ICANS), manufacturing time (3-4 weeks), and — critically — CD19 antigen loss in approximately 20-40% of relapses post-CAR-T. Obecabtagene autoleucel (obe-cel) represents an engineering advance targeting reduced T-cell exhaustion through a fast-off binder, with Phase 2 data suggesting potentially higher response rates and lower neurotoxicity.

The Post-CAR-T Problem

As CD19 CAR-T becomes standard care for R/R B-ALL, the "post-CAR-T" relapse population is growing. These patients have exhausted the most powerful available therapy and often have CD19-negative disease that is invisible to CD19-directed agents. The leading strategies include: (1) CD22-directed therapy — inotuzumab ozogamicin or CD22 CAR-T cells, exploiting an antigen that remains expressed after CD19 loss; (2) allogeneic transplant in patients who achieve remission; (3) novel combinations targeting non-CD19/CD22 pathways. NCI's NCT07328503 testing CD22 CAR-T after commercial CD19 CAR-T is one of the most clinically important trials currently opening in adult ALL.

T-Cell ALL: A Different Disease

T-cell ALL (T-ALL) lacks CD19 and CD22, making the blinatumomab/inotuzumab/CD19 CAR-T toolkit largely inapplicable. T-ALL has its own genomic landscape: NOTCH1/FBXW7 mutations (present in ~60%, associated with better prognosis), TAL1 rearrangements, LMO2 overexpression, and JAK/STAT pathway alterations. Treatment relies primarily on chemotherapy intensification with nelarabine (a T-cell-selective purine analog). Novel approaches in development include: venetoclax (BCL-2 expression in T-ALL), gamma-secretase inhibitors (targeting NOTCH1 signaling), CD7-directed CAR-T cells, and JAK inhibitors for JAK-mutant T-ALL. T-ALL remains an area of significant unmet need where the immunotherapy revolution has had limited impact to date.

Key Questions Driving ALL Trials in 2026

• Can blinatumomab eliminate chemotherapy in adult ALL? The MDACC experience in Ph+ ALL (blinatumomab + ponatinib, no chemo) is being extended — can similar approaches work in Ph-negative ALL?
• When to use inotuzumab vs. CD19 CAR-T in R/R B-ALL? Both achieve high response rates; sequencing depends on transplant eligibility, VOD risk, manufacturing time, and center experience.
• How to manage post-CD19 CAR-T relapse? CD22-directed approaches are the leading strategy; head-to-head comparisons are limited.
• Can venetoclax add value in ALL? BCL-2 expression varies by ALL subtype; trials are testing venetoclax combinations in both frontline and relapsed settings.
• What is the optimal treatment for Ph-like ALL? Ph-like ALL has diverse genetic alterations (ABL-class fusions, JAK-STAT alterations, etc.) — precision medicine approaches matching therapy to molecular subtype are being tested.

Related Disease Pages

• Acute Myeloid Leukemia (AML) Clinical Trials — menin inhibitors, venetoclax, FLT3
• Chronic Lymphocytic Leukemia (CLL) Clinical Trials — BTK inhibitors, sonrotoclax
• Leukemia Clinical Trials Overview — all leukemia subtypes
• DLBCL Clinical Trials — CAR-T, bispecific antibodies
• Non-Hodgkin Lymphoma Overview